natasa rajicic, ScD Winter 2016
NATASA RAJICIC
135 Division St,4D
New York, NY 10002
917 882 3471
dogzees@gmail.com
Pfizer...
of 1

Natasa Rajicic ScD 2016

Published on: Mar 3, 2016
Source: www.slideshare.net


Transcripts - Natasa Rajicic ScD 2016

  • 1. natasa rajicic, ScD Winter 2016 NATASA RAJICIC 135 Division St,4D New York, NY 10002 917 882 3471 dogzees@gmail.com Pfizer, New York, NY Statistics Group Lead Manager of 3 statisticians across 3 productsin2 therapeuticareas Director,2011 – Present Assoc.Director,2006 – 2011 MassachusettsGeneral Hospital, Boston,MA Doctoral Student/Consulting Biostatistician,2003 – 2006 Center for BiostatisticsinAIDS Research, Boston, MA Biostatistician junior, 1996 – 1998 senior,1999 – 2001 Education Harvard School of PublicHealth, Boston,MA - ScD Biostatistics,2006 Harvard UniversitySchool of ContinuingEd., Cambridge,MA - Certificate of Administration and Management,2002 WestVirginiaUniversity, Morgantown,WV - MS Statistics,1996 - BA Mathematics,1994 Summary Enthusiasticstatistical leaderfordata-drivendecisionmaking. Fueledby innovation,adaptability,and highachievement. Motivatedbychange andideas. Areas of Expertise and Skills Late-stage drug development Due diligence Regulatory responses Rare diseasestudies Communication and influencein cross- functional teams Knowledge management R/EAST/SAS/Spotfire ProfessionalAccomplishments  Leda cross-functionalteamtoa successful regulatorysubmissionforarare disease post-approval safetysurveillance study  Coordinatedstatistical,programming,andmedical resourcesonover20 accepted abstracts andmanuscriptsfollowingaproductlaunch  Consultedexecutive steeringcommittee foralarge time-to-eventCV trial  Impactedbusinessdevelopmentdecisionsindue diligence projects  Presenteddatainsightstoscientificadvisoryboardsand governance bodies  Directedtwo interimanalysesthroughastatistical vendor  Servedasan independentstatisticianondatasafetyreviewcommittees  Stressedstatistical rigorinpreparationof numerousregulatoryresponses  Identifiedrisk/benefitanalysesinsupportof productsafetyprofilesand disseminationof medical information  Collaboratedwithandinfluencedmedical,marketing,and commercial lines  Elicitedresearchideas ongenomicsintraumaandburnfromamedicalconsortium  Developedanovelmethodforthesurvivalanalysisoflongitudinalmicroarrays Selected Publications (from 30+) 1.ShireNJ,Rouster S,RajicicN,Sherman KE.OcculthepatitisBin HIV-infected patients.JAIDS 2004 2.RajicicN,etal.Survival analysisof longitudinalmicroarrays. Bioinformatics 2006 3.RajicicN,FinkelsteinDM,SchoenfeldDA.Analysisof therelationshipbetween longitudinal gene expressionsand ordered categorical eventdata.Statin Med 2009 4.RajicicN,etal.Identification and interpretationof longitudinal geneexpressionchangesin trauma.PLoS One2010 5.Schoenfeld DA,RajicicN,etal.Atestfor therelationship between a time-varyingmarker and both recovery and progression with missingdata. Statin Med 2010 6.Patel NR,AnkolekarS,AntonijevicZ,RajicicN.Amodel for maximizingthevalueof Ph 3 drug developmentportfoliosincorporatingbudgetconstraintsand risk.Statin Med 2013 7.Counts DR,Silverman LA, Rajicic N.etal.A4-Year,open-label,multicenter,randomized trial of Genotropin®Growth Hormonein patientswith idiopathic shortstature:Analysisof 4-year data comparingefficacy,efficiency,and safety between an individualized,target-driven regimen and standarddosing.HormRes Paediatr2015

Related Documents